
Redeye Initiates Coverage of Corline Biomedical

Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in coating solutions for the medical technology industry and transplantation clinics. With its partner Kardium expected to enter the commercial stage in 2026e, we anticipate a significant sales uptick. Our fair value range suggests a substantial upside, supported by several key catalysts linked to Kardium's product launch.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Redeye Initiates Coverage of Corline Biomedical](#)